Status:

RECRUITING

Stimulant Effects on Disruptive Behavior

Lead Sponsor:

Matthew J O'Brien, PhD, BCBA-D

Conditions:

Attention Deficit Hyperactivity Disorder

Problem Behavior

Eligibility:

All Genders

48-12 years

Phase:

PHASE4

Brief Summary

The goal of this study is to determine the effects of stimulant medication on disruptive behavior, function, preference and choice; however, it is primarily methodological and will add to current rese...

Detailed Description

This study includes the consent, a pre-visit interview, and two assessment phases occurring at weekly visits. Phase I includes four visits, each lasting approximately 2 hours. Phase II includes four v...

Eligibility Criteria

Inclusion

  • Participant must be a child or adolescent between the ages of 4 years, 0 months, and 13 years, 0 months (participants must not be older than 12 years, 11 months).
  • Participant must have a valid diagnosis of attention deficit/hyperactivity disorder (AD/HD). No specification of type (e.g., predominately inattentive type, predominately hyperactive-impulsive type, or combined type) will be necessary.
  • Participant must exhibit disruptive behavior, defined as one or more of the following:
  • physical or verbal aggression towards others: Hitting, kicking, biting, scratching, choking, spitting at, or throwing items at another person, and/or making insults, threats, or swearing at another person.
  • self-injury: Hitting self, biting self, banging head on an object/hard surface, pinching self, or scratching self with visual skin damage.
  • destruction: Damaging (or attempts to damage) personal or public property (e.g., breaking an object into two or more pieces, using an object to break other objects, ripping objects or parts of objects from walls, floors, or furniture, and denting cars, objects, or walls.)
  • noncompliance:Regular occurrence of verbal refusal (e.g., saying "no", "I don't want to", "I won't do it" or "not now") to any academic or non-academic request, and/or any response that does not match the delivered instruction within 30 seconds from the time the instruction was delivered.
  • tantrum:Crying (i.e., any vocalizations \[sounds or words\] accompanied by facial contraction with and without tears for any period of time) and/or screaming (occurrence of vocalizations above normal conversational volume for any period of time), with or without body flailing.
  • an active diagnosis of disruptive behavior disorder or oppositional defiant disorder.
  • Participant must already be prescribed a stimulant medication for the treatment of AD/HD symptoms and at an approved dose for age.

Exclusion

  • a diagnosis of autism, conduct disorder, or intellectual disability in the moderate, severe or profound range.
  • prescribed or taking a stimulant dosage outside of recommended therapeutic range.

Key Trial Info

Start Date :

October 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2027

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT03420339

Start Date

October 1 2018

End Date

August 1 2027

Last Update

March 17 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States, 52242